Skip to main content


Fig. 1 | Diabetology & Metabolic Syndrome

Fig. 1

From: Evaluation of the efficacy and safety of lixisenatide add-on treatment to basal insulin therapy among T2DM patients with different body mass indices from GetGoal trials

Fig. 1

Mean Change in HbA1c of Study Groups (a) and Proportions of Study Groups that Achieved an Endpoint HbA1c <7 % (b). Statistical significance of differences in mean changes in HbA1c was determined by ANOVA with standard error presented and that of the differences in the proportions of T2DM patients with an endpoint HbA1c <7 % was determined by χ2 test

Back to article page